FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martine Van Glabbeke

Research Profile

Concepts & Ideas

Disorders

Chemicals & Drugs

Procedures

Geographic Areas

Europe

Co-author Network

Publications

TOP 3
Bernd Kasper; Monia Ouali; Jean-Yves Blay; Vivien H C Bramwell; Peter Hohenberger; Martine Van Glabbeke; Penella J Woll; Patrick Schöffski
Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Philippe A Cassier; Maria Debiec-Rychter; Florence Duffaud; Jean-François Emile; Elena Fumagalli; Peter Hohenberger; Ian Judson; Bruno Landi; Serge Leyvraz; Javier Martin-Broto; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Jaap Verweij; Antoine Adenis; François Bertucci; Jean-Yves Blay; Emmanuelle Bompas; Olivier Bouché; Paolo Casali
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Jeremy S Whelan; V H C Bramwell; R J Grimer; P C W Hogendoorn; J M Hook; R C Jinks; I J Lewis; Anne McTiernan; Marianne A Nooij; Matthew R Sydes; A H M Taminiau; L Trani; Barbara Uscinska; Martine Van Glabbeke; H Gelderblom
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martine Van Glabbeke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Bernd Kasper; Monia Ouali; Jean-Yves Blay; Vivien H C Bramwell; Peter Hohenberger; Martine Van Glabbeke; Penella J Woll; Patrick Schöffski
Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
European journal of cancer (Oxford, England : 1990) 2013;49(2):449-56.
2012: Philippe A Cassier; Maria Debiec-Rychter; Florence Duffaud; Jean-François Emile; Elena Fumagalli; Peter Hohenberger; Ian Judson; Bruno Landi; Serge Leyvraz; Javier Martin-Broto; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Jaap Verweij; Antoine Adenis; François Bertucci; Jean-Yves Blay; Emmanuelle Bompas; Olivier Bouché; Paolo Casali
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4458-64.
2012: Jeremy S Whelan; V H C Bramwell; R J Grimer; P C W Hogendoorn; J M Hook; R C Jinks; I J Lewis; Anne McTiernan; Marianne A Nooij; Matthew R Sydes; A H M Taminiau; L Trani; Barbara Uscinska; Martine Van Glabbeke; H Gelderblom
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(6):1607-16.
2012: Anne McTiernan; Marianne A Nooij; Matthew R Sydes; Antonie H M Taminiau; Barbara Uscinska; Martine Van Glabbeke; Vivien Bramwell; Hans Gelderblom; Pancras C W Hogendoorn; Jane M Hook; Rachel C Jinks; Ian J Lewis; Jeremy S Whelan
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
European journal of cancer (Oxford, England : 1990) 2012;48(5):703-12.
2011: N Penel; Martine Van Glabbeke; S Marreaud; M Ouali; J Y Blay; P Hohenberger
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(6):1266-72.
2011: Hans Gelderblom; Rachel C Jinks; Matthew R Sydes; Vivien H C Bramwell; Martine Van Glabbeke; Robert J Grimer; Pancras C W Hogendoorn; Anne McTiernan; Ian J Lewis; Marianne A Nooij; Antonie H M Taminiau; Jeremy Whelan
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.
European journal of cancer (Oxford, England : 1990) 2011;47(6):895-902.
2011: Judith R Kroep; M Ouali; Hans Gelderblom; A Le Cesne; T J A Dekker; Martine Van Glabbeke; P C W Hogendoorn; P Hohenberger
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(1):207-14.
2010: Marco Novelli; Sabrina Rossi; Manuel Rodriguez-Justo; Philippe Taniere; Beatrice Seddon; Luisa Toffolatti; Chiara Sartor; Pancras C W Hogendoorn; Raf Sciot; Martine Van Glabbeke; Jaap Verweij; Jean Yves Blay; Peter Hohenberger; Adrienne M Flanagan; Angelo P Dei Tos
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.
Histopathology 2010;57(2):259-70.
2010: Marinus H J van Oers; Martine Van Glabbeke; Livia Giurgea; Richard J Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Mars van t Veer; Andrej Vranovsky; Harald Holte; Anton Hagenbeek
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2853-8.
2010: Marinus H J van Oers; Evelyn Tönnissen; Martine Van Glabbeke; Livia Giurgea; Joop H Jansen; Richard J Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Andrej Vranovsky; Harald Holte; Anton Hagenbeek; Bert A van der Reijden
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2246-52.
2010: Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1772-9.
2010: Stefan Sleijfer; Monia Ouali; Martine Van Glabbeke; Anders Krarup-Hansen; Sjoerd Rodenhuis; Axel Le Cesne; Pancras C W Hogendoorn; Jaap Verweij; Jean-Yves Blay
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
European journal of cancer (Oxford, England : 1990) 2010;46(1):72-83.
2009: Axel Le Cesne; Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Michael Findlay; Peter Reichardt; Rolf Issels; Ian Judson; Patrick Schoffski; Serge Leyvraz; Binh Nguyen Bui; Pancras C W Hogendoorn; Raf Sciot; Jean-Yves Blay
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3969-74.
2009: ISABELLE RAY COQUARD; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras Hogendoorn; Philippe A Cassier; Armelle Dufresne; Jean-Yves Blay
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Cancer research 2009;69(13):5383-91.
2009: Stefan Sleijfer; ISABELLE RAY COQUARD; Zsuzsa Papai; Axel Le Cesne; Michelle Scurr; Patrick Schöffski; Françoise Collin; Lini Pandite; Sandrine Marreaud; Annick De Brauwer; Martine Van Glabbeke; Jaap Verweij; Jean-Yves Blay
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3126-32.
2009: Salvatore Romeo; Maria Debiec-Rychter; Martine Van Glabbeke; Heidi Van Paassen; Paola Comite; Ronald van Eijk; Jan Oosting; Jaap Verweij; Philippe Terrier; Ulrike Schneider; Raf Sciot; Jean Yves Blay; Pancras Hogendoorn
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4191-8.
2009: Daphne de Jong; Ad Koster; Anton Hagenbeek; John M M Raemaekers; Dennis Veldhuizen; Sabien Heisterkamp; Jan Paul de Boer; Martine Van Glabbeke
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
Haematologica 2009;94(1):70-7.
2008: Raf Sciot; Maria Debiec-Rychter; Soren Daugaard; Cyril Fisher; Francoise Collin; Martine Van Glabbeke; Jaap Verweij; Jean-Yves Blay; Pancras Hogendoorn
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
European journal of cancer (Oxford, England : 1990) 2008;44(13):1855-60.
2008: ISABELLE RAY COQUARD; Axel Le Cesne; Jeremy S Whelan; Patrick Schoffski; Binh N Bui; Jaap Verweij; Sandrine Marreaud; Martine Van Glabbeke; Pancras Hogendoorn; Jean-Yves Blay
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
The oncologist 2008;13(4):467-73.
2007: Paul Lorigan; Jaap Verweij; Zsuzsa Papai; Sjoerd Rodenhuis; Axel Le Cesne; Michael G Leahy; John A Radford; Martine Van Glabbeke; Anne Kirkpatrick; Pancras Hogendoorn; Jean-Yves Blay
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3144-50.
2007: Jaap Verweij; Paolo G Casali; Dusan Kotasek; Axel Le Cesne; Peter Reichard; Ian R Judson; Rolf Issels; Allan T van Oosterom; Martine Van Glabbeke; Jean-Yves Blay
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
European journal of cancer (Oxford, England : 1990) 2007;43(6):974-8.
2007: Peter Reichardt; Ole Steen Nielsen; S Bauer; Jörg Thomas Hartmann; Patrick Schöffski; T B Christensen; Daniel Pink; S Daugaard; Sandrine Marreaud; Martine Van Glabbeke; J Y Blay
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2007;43(6):1017-22.
2007: Ian J Lewis; Marianne A Nooij; Jeremy Whelan; Matthew R Sydes; Robert Grimer; Pancras Hogendoorn; Muhammad A Memon; Simon Weeden; Barbara M Uscinska; Martine Van Glabbeke; Anne Kirkpatrick; Esther Hauben; Alan W Craft; Antonie H M Taminiau
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Journal of the National Cancer Institute 2007;99(2):112-28.
2007: Michael Leahy; ISABELLE RAY COQUARD; Jaap Verweij; Axel Le Cesne; Florence Duffaud; Pancras Hogendoorn; Camilla Fowst; Christine de Balincourt; Eugenio Donato Di Paola; Martine Van Glabbeke; Ian Judson; Jean-Yves Blay
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2007;43(2):308-15.
2006: Elizabeth C Moser; Hanneke C Kluin-Nelemans; Patrice Carde; Jacobus H Meerwaldt; Umberto Tirelli; Berthe M P Aleman; Joke W Baars; José Thomas; Martine Van Glabbeke; Evert M Noordijk
Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
International journal of radiation oncology, biology, physics 2006;66(4):1168-77.
2006: Marinus H J van Oers; Richard J Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars B van't Veer; Andrej Vranovsky; Harald Holte; Martine Van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
Blood 2006;108(10):3295-301.
2006: Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine Van Glabbeke; Hanneke C Kluin-Nelemans
Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Haematologica 2006;91(11):1481-8.
2006: Ole Steen Nielsen; Peter Reichardt; T B Christensen; Daniel Pink; S Daugaard; C Hermans; Sandrine Marreaud; Martine Van Glabbeke; J Blay; I Judson
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2303-9.
2006: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; R John Simes; Axel Le Cesne; Peter Reichardt; Rolf Issels; Ian R Judson; Allan T van Oosterom; Jean-Yves Blay
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
European journal of cancer (Oxford, England : 1990) 2006;42(14):2277-85.
2006: Julie Francart; Catherine Legrand; Richard Sylvester; Martine Van Glabbeke; Jan P van Meerbeeck; Annie Robert
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3007-12.
2006: Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
European journal of cancer (Oxford, England : 1990) 2006;42(8):1093-103.
2006: Anton Hagenbeek; Houchingue Eghbali; Silvio Monfardini; Umberto Vitolo; Peter J Hoskin; Christiane De Wolf-Peeters; Ken MacLennan; Elvira Staab-Renner; Joachim Kalmus; Astrid Schott; Ivana Teodorovic; Anastassia Negrouk; Martine Van Glabbeke; Robert Marcus
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1590-6.
2006: Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Saskia Le Cessie; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine Van Glabbeke; Hanneke C Kluin-Nelemans
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.
Blood 2006;107(7):2912-9.
2005: Jacques Bernier; Jay S Cooper; Thomas F Pajak; Martine Van Glabbeke; Jean Bourhis; Arlene A Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; K. Kian Ang; Jean-Louis Lefèbvre
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Head & neck 2005;27(10):843-50.
2005: Elizabeth C Moser; Evert M Noordijk; Patrice Carde; Umberto Tirelli; Joke W Baars; Jose Thomas; Dominique Bron; Jacobus H Meerwaldt; Martine Van Glabbeke; John M M Raemaekers; Hanneke C Kluin-Nelemans
Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
Clinical lymphoma & myeloma 2005;6(2):122-30.
2005: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; ISABELLE RAY COQUARD; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5795-804.
2005: John Zalcberg; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Reichardt; Jean-Yves Blay; Marcus Schlemmer; Martine Van Glabbeke; Michelle Brown; Ian R Judson
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1751-7.
2005: Jean-Yves Blay; Sylvie Bonvalot; Paolo Casali; H Choi; M Debiec-Richter; A P Dei Tos; J-F Emile; Alessandro Gronchi; Pancras Hogendoorn; Heikki Joensuu; Axel Le Cesne; J McClure; J Mac Clure; J Maurel; N Nupponen; ISABELLE RAY COQUARD; P Reichardt; R Sciot; S Stroobants; Martine Van Glabbeke; Allan van Oosterom; George D Demetri
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):566-78.
2005: Ian Judson; Peiming Ma; Bin Peng; Jaap Verweij; Amy Racine; Eugenio Donato Di Paola; Martine Van Glabbeke; Sasa Dimitrijevic; Michelle Scurr; Herlinde Dumez; Allan van Oosterom
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
Cancer chemotherapy and pharmacology 2005;55(4):379-86.
2005: Axel Le Cesne; Jean-Yves Blay; Ian Judson; Allan van Oosterom; Jaap Verweij; John Radford; Paul Lorigan; S Rodenhuis; ISABELLE RAY COQUARD; Sylvie Bonvalot; Françoise Collin; José Jimeno; Eugenio Donato Di Paola; Martine Van Glabbeke; Ole Steen Nielsen
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):576-84.
2004: Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Lancet 2004;364(9440):1127-34.
2004: Sophie D Fosså; Gerald H J Mickisch; P H M De Mulder; Simon Horenblas; Allan T van Oosterom; Hein van Poppel; Martin Fey; Jelle J Croles; Linda de Prijck; Martine Van Glabbeke
Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Cancer 2004;101(3):533-40.
2004: J-Y Blay; A Le Cesne; Jaap Verweij; Michelle Scurr; C Seynaeve; Sylvie Bonvalot; P Hogendoorn; J Jimeno; Veerle Evrard; Martine Van Glabbeke; Ian Judson
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(9):1327-31.
2004: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine Van Glabbeke
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
The New England journal of medicine 2004;350(19):1945-52.
2004: Maria Debiec-Rychter; Herlinde Dumez; Ian Judson; Bartosz Wasag; Jaap Verweij; M Brown; Sasa Dimitrijevic; Raf Sciot; Michel Stul; H Vranck; Michelle Scurr; Anne Hagemeijer; Martine Van Glabbeke; Allan T van Oosterom
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2004;40(5):689-95.
2004: Elizabeth C Moser; Evert M Noordijk; Martine Van Glabbeke; Ivana Teodorovic; C de Wolf-Peeters; Patrice Carde; Joke W Baars; Umberto Tirelli; John M M Raemaekers; Johanna C Kluin-Nelemans
Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials.
European journal of cancer (Oxford, England : 1990) 2004;40(4):474-80.
2003: Philip Poortmans; Hanneke C Kluin-Nelemans; Hanny Haaxma-Reiche; Mars B van't Veer; Mads Hansen; Pierre Soubeyran; Martin J B Taphoorn; José Thomas; Martin J van den Bent; Martin Fickers; Gustaaf W van Imhoff; Cynthia Rozewicz; Ivana Teodorovic; Martine Van Glabbeke
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4483-8.
2003: J-Y Blay; Martine Van Glabbeke; J Verweij; A T van Oosterom; A Le Cesne; J W Oosterhuis; I Judson; Ole Steen Nielsen
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.
European journal of cancer (Oxford, England : 1990) 2003;39(1):64-9.
2002: A T van Oosterom; Henning T Mouridsen; Ole Steen Nielsen; Per Dombernowsky; K Krzemieniecki; I Judson; L Svancarova; D Spooner; C Hermans; Martine Van Glabbeke; J Verweij
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
European journal of cancer (Oxford, England : 1990) 2002;38(18):2397-406.
2002: Marinus H J van Oers; Anton Hagenbeek; Martine Van Glabbeke; Ivana Teodorovic
Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Annals of hematology 2002;81(10):553-7.
2002: Allan T van Oosterom; Ian R Judson; Jaap Verweij; Sigrid Stroobants; Herlinde Dumez; Eugenio Donato di Paola; Raf Sciot; Martine Van Glabbeke; Sasa Dimitrijevic; Ole Steen Nielsen
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 5():S83-7.
2002: Harry Bartelink; Walter Van den Bogaert; Jean-Claude Horiot; Jos Jager; Martine Van Glabbeke
Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
European journal of cancer (Oxford, England : 1990) 2002;38(5):667-73.
2002: Martine Van Glabbeke; W Steward; J P Armand
Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?
European journal of cancer (Oxford, England : 1990) 2002;38(5):635-8.
2002: L Svancárová; Jean-Yves Blay; Ian R Judson; Q G C M van Hoesel; Allan T van Oosterom; Axel Le Cesne; HJ Keizer; C Hermans; Martine Van Glabbeke; Jaap Verweij; Pancras Hogendoorn; Ole Steen Nielsen
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38(4):556-9.
2002: Martine Van Glabbeke; J Verweij; I Judson; Ole Steen Nielsen
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.
European journal of cancer (Oxford, England : 1990) 2002;38(4):543-9.
2002: C Lardot; W Steward; Martine Van Glabbeke; J-P Armand
Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S24-30.
2002: Abul B M F Karim; Denes Afra; Philippe Cornu; Norman Bleehan; Simon Schraub; Olivier De Witte; François Darcel; Sally P Stenning; Marianne Pierart; Martine Van Glabbeke
Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.
International journal of radiation oncology, biology, physics 2002;52(2):316-24.
2001: Allan T van Oosterom; Ian Judson; Jaap Verweij; S Stroobants; Eugenio Donato di Paola; Sasa Dimitrijevic; M Martens; A Webb; Raf Sciot; Martine Van Glabbeke; S Silberman; Ole Steen Nielsen
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet 2001;358(9291):1421-3.
2001: Jean-François Bosset; Jean-Claude Horiot; HP Hamers; L Cionini; Harry Bartelink; R Caspers; M Untereiner; E Ciambelloti; Marianne Pierart; Martine Van Glabbeke
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;61(1):7-13.
2001: E Gortzak; A Azzarelli; J Buesa; V H C Bramwell; Frits van Coevorden; A N van Geel; A Ezzat; A Santoro; J W Oosterhuis; Martine Van Glabbeke; A Kirkpatrick; Jaap Verweij
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1096-103.
2000: S J Gwyther; Ole Steen Nielsen; Ian R Judson; Martine Van Glabbeke; Jaap Verweij
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
Anti-cancer drugs 2000;11(6):433-7.
2000: Axel Le Cesne; Ian Judson; D Crowther; Sjoerd Rodenhuis; HJ Keizer; Q G C M van Hoesel; Jean-Yves Blay; J Frisch; Martine Van Glabbeke; C Hermans; Allan van Oosterom; T Tursz; Jaap Verweij
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2676-84.
2000: Jaap Verweij; S M Lee; W Ruka; J Buesa; R Coleman; R van Hoessel; Caroline Seynaeve; Eugenio Donato Di Paola; Martine Van Glabbeke; D Tonelli; Ian R Judson
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2081-6.
2000: Jacques Bernier; Juliana Denekamp; A Rojas; E Minatel; Jean-Claude Horiot; HP Hamers; Paolo Antognoni; O Dahl; P Richaud; Martine Van Glabbeke; M Piérart
ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2000;55(2):111-9.
2000: Patrick Therasse; Arbuck Susan; Elizabeth A Eisenhauer; J Wanders; Richard S. Kaplan; Lawrence V Rubinstein; J Verweij; Martine Van Glabbeke; A T van Oosterom; Michaele C Christian; S G Gwyther
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
Journal of the National Cancer Institute 2000;92(3):205-16.
2000: Ole Steen Nielsen; Ian Judson; Q G C M van Hoesel; Axel Le Cesne; HJ Keizer; Jean-Yves Blay; Allan van Oosterom; John A Radford; L Svancárová; K Krzemienlecki; C Hermans; Martine Van Glabbeke; J W Oosterhuis; Jaap Verweij
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2000;36(1):61-7.
1999: Paul A Voûte; Robert Souhami; Marianne A Nooij; R Somers; H Cortés-Funes; Jan W van der Eijken; J Pringle; Pancras Hogendoorn; A Kirkpatrick; Barbara Uscinska; Martine Van Glabbeke; D Machin; Simon Weeden
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(10):1211-8.
1999: V H Bramwell; W P Steward; Marianne A Nooij; J Whelan; Alan W Craft; R J Grimer; A H Taminau; S R Cannon; A J Malcolm; Pancras Hogendoorn; Barbara Uscinska; A L Kirkpatrick; D Machin; Martine Van Glabbeke
Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3260-9.
1999: R Miralbell; F Mornex; R Greiner; Michel Bolla; G Storme; M Hulshof; J Bernier; Juliana Denekamp; Ana M Rojas; Marianne Pierart; Martine Van Glabbeke; René-Olivier Mirimanoff
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3143-9.
1999: Catherine Lhommé; Pierre Fumoleau; Pierre Fargeot; Y Krakowski; V Dieras; Jean Chauvergne; P Vennin; P Rebattu; H Roche; Jean-Louis Misset; M A Lentz; Martine Van Glabbeke; A Matthieu-Boué; Dominique Mignard; Bernard Chevallier
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3136-42.
1999: Jacques Bernier; Juliana Denekamp; A Rojas; M Trovò; Jean-Claude Horiot; HP Hamers; Paolo Antognoni; O Dahl; P Richaud; Johannes H A M Kaanders; Martine Van Glabbeke; M Piérart
ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1999;52(2):149-56.
1999: PJ Woll; Ian Judson; S M Lee; S Rodenhuis; Ole Steen Nielsen; J M Buesa; Paul Lorigan; S Leyvraz; C Hermans; Martine Van Glabbeke; J Verweij
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 1999;35(3):410-2.
1999: Martine Van Glabbeke; Allan T van Oosterom; J W Oosterhuis; Henning Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):150-7.
1999: A Pawinski; D Crowther; HJ Keizer; Paul A Voûte; R Somers; Martine Van Glabbeke; MA Lentz; Allan T van Oosterom
The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma.
European journal of cancer (Oxford, England : 1990) 1999;35(1):163-4.
1998: Ole Steen Nielsen; Per Dombernowsky; Henning Mouridsen; D Crowther; Jaap Verweij; J Buesa; W Steward; S Daugaard; Martine Van Glabbeke; A Kirkpatrick; T Tursz
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
British journal of cancer 1998;78(12):1634-9.
1998: Marian Degardin; J Oliveira; L Geoffrois; Frédéric Rolland; Jean-Pierre Armand; P Bastit; Jean Chauvergne; Pierre Fargeot; Martine Van Glabbeke; M A Lentz; P Tresca; J Boudillet; Pierre Fumoleau; P Cappelaere
An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1103-7.
1998: Robert Paridaens; Josee-Anne Roy; Marianne A Nooij; Jan G M Klijn; S J Houston; Louk V A M Beex; J Vinholes; E Tomiak; Ann Van Vreckem; C Langenaeken; Martine Van Glabbeke; Martine J Piccart
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Anti-cancer drugs 1998;9(1):29-35.
1998: Anton Hagenbeek; Patrice Carde; Jacobus H Meerwaldt; R Somers; José Thomas; Robrecht De Bock; John M M Raemaekers; Achiel Van Hoof; Christiane De Wolf-Peeters; Martine Van Glabbeke
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):41-7.
1998: Umberto Tirelli; D Errante; Martine Van Glabbeke; Ivana Teodorovic; Johanna C Kluin-Nelemans; José Thomas; Dominique Bron; G Rosti; R Somers; Vittorina Zagonel; Evert M Noordijk
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):27-34.
1997: Elizabeth A Eisenhauer; J B Vermorken; Martine Van Glabbeke
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments].
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):963-8.
1997: Robert Souhami; Alan W Craft; Jan W van der Eijken; Marianne A Nooij; D Spooner; V H Bramwell; R Wierzbicki; A J Malcolm; A Kirkpatrick; Barbara Uscinska; Martine Van Glabbeke; D Machin
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.
Lancet 1997;350(9082):911-7.
1997: Martine J Piccart; Jan G M Klijn; Robert Paridaens; Marianne A Nooij; Louis Mauriac; R Coleman; Marijke Bontenbal; Ahmad Awada; J Selleslags; Ann Van Vreckem; Martine Van Glabbeke
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(9):3149-55.
1997: Ahmad Awada; Ann Van Vreckem; Robert Paridaens; Peter Bruning; Jan G M Klijn; E Tomiak; J Vinholes; Josee-Anne Roy; Z Kusenda; G Hoctin Boes; Martine Van Glabbeke; Martine J Piccart
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1173-6.
1997: Harry Bartelink; F Roelofsen; F Eschwege; P Rougier; Jean-François Bosset; D G Gonzalez; D Peiffert; Martine Van Glabbeke; Marianne Pierart
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):2040-9.
1996: A B Karim; B Maat; R Hatlevoll; Johan Menten; E H Rutten; D G Thomas; F Mascarenhas; Jean-Claude Horiot; L M Parvinen; M van Reijn; J J Jager; M G Fabrini; A M van Alphen; H P Hamers; L Gaspar; E Noordman; Marianne Pierart; Martine Van Glabbeke
A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.
International journal of radiation oncology, biology, physics 1996;36(3):549-56.
1996: Philippe Rougier; C van Pottelsberghe; T Kok; Bernard Paillot; T Wagener; J De Greve; M C Fabri; B Gerard; Martine Van Glabbeke; Harry Bleiberg
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group).
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1432-3.
1996: Thierry Conroy; P L Etienne; Antoine Adenis; D J Wagener; Bernard Paillot; Eric François; Laurent Bedenne; J H Jacob; J F Seitz; Harry Bleiberg; C Van Pottelsberghe; Martine Van Glabbeke; F M Delgado; S Merle; Jacques A Wils
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):164-70.
1995: Ivana Teodorovic; S Pittaluga; Johanna C Kluin-Nelemans; J H Meerwaldt; Anton Hagenbeek; Martine Van Glabbeke; R Somers; Luc Bijnens; Evert M Noordijk; C D Peeters
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2819-26.
1995: Walter Van den Bogaert; E van der Schueren; Jean-Claude Horiot; M De Vilhena; S Schraub; V Svoboda; G Arcangeli; M de Pauw; Martine Van Glabbeke
The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;35(2):91-9.
1995: Walter Van den Bogaert; E van der Schueren; Jean-Claude Horiot; M De Vilhena; S Schraub; V Svoboda; G Arcangeli; M de Pauw; Martine Van Glabbeke
The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1995;35(2):100-6.
1994: Q G van Hoesel; Jaap Verweij; G Catimel; M Clavel; P Kerbrat; A T van Oosterom; J Kerger; T Tursz; Martine Van Glabbeke; C van Pottelsberghe
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):539-42.
1994: Jaap Verweij; I Judson; W Steward; R Coleman; P Woll; C van Pottelsberghe; Martine Van Glabbeke; H Mouridsen
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):842-3.
1994: A Ptaszynski; Walter Van den Bogaert; Martine Van Glabbeke; Marianne Pierart; Harry Bartelink; Jean-Claude Horiot; A Fourquet; Henk Struikmans; H Hamers; R P Müller
Patient population analysis in EORTC trial 22881/10882 on the role of a booster dose in breast-conserving therapy.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2073-81.
1993: Jaap Verweij; K Krzemieniecki; T Kok; A Poveda; C van Pottelsberghe; Martine Van Glabbeke; H Mouridsen
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):208-9.
1993: Jacek Jassem; H Karnicka-Młodkowska; C van Pottelsberghe; Martine Van Glabbeke; M A Noseda; Andrea Ardizzoni; F Gozzelino; A Planting; nico van zandwijk
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 1993;29A(12):1720-2.
1993: Martine Van Glabbeke; A T van Oosterom; W Steward; J Verweij; H Mouridsen
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
European journal of cancer (Oxford, England : 1990) 1993;29A(14):1943-7.
1992: G Stoter; A Akdas; S D Fosså; Stanley B Kaye; C J van Groeningen; J Renard; Martine Van Glabbeke
High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(7):577-8.
1991: Patrice Carde; J H Meerwaldt; Martine Van Glabbeke; R Somers; Mathieu Monconduit; José Thomas; C de Wolf-Peeters; B de Pauw; A Tanguy; Johanna C Kluin-Nelemans
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(6):431-5.
1990: Adrian C Begg; Ingrid Hofland; Luc Moonen; Harry Bartelink; S Schraub; P Bontemps; R Le Fur; Walter Van den Bogaert; R Caspers; Martine Van Glabbeke
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report.
International journal of radiation oncology, biology, physics 1990;19(6):1449-53.